Sveriges Riksbank
10.3.2026 09:30:00 CET | Globenewswire | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
| Bid date, 2026-03-10 | |
| Auction date | 2026-03-10 |
| Settlement date | 2026-03-11 |
| Maturity Date | 2026-03-18 |
| Nominal amount | 521 billion SEK |
| Interest rate | 1.75 % |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Bids are made to phone number | 08-696 69 70 |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 521 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 521 billion SEK |
| Expected excess liquidity at full allotment | 0 billion SEK |
Stockholm, 2026-03-10
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ZenaTech Inc.10.3.2026 13:00:00 CET | Press release
ZenaTech’s ZenaDrone Commences Development of IQ Glider, an Autonomous Marine Drone Launch and Refueling Station for the ZenaDrone 2000 Intercept Drone
Orion Oyj10.3.2026 12:50:00 CET | Press release
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
Wood Mackenzie10.3.2026 12:27:04 CET | Press release
Oil could hit $150/bbl as Gulf shutdown of 15 million b/d forces demand destruction
Investeringsforeningen SparDanmark Invest10.3.2026 12:15:18 CET | Pressemeddelelse
Investeringsforeningen SparDanmark Invest – Offentliggørelse af Årsrapport 2025
NMD Pharma10.3.2026 12:03:19 CET | Press release
NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom